Researchers looking to buy tesamorelin 10mg + ipamorelin 3mg for laboratory studies may consider this fixed-ratio peptide formulation when their experimental design requires both peptide components within the same preparation. Manufactured by Novera Compounds, the blend contains tesamorelin and ipamorelin in a 10:3 ratio and is supplied as a lyophilized research material. Rather than representing a therapeutic combination, this formulation serves as a research reagent for investigating growth hormone pathway activity under controlled conditions. The material allows laboratories to examine how separate peptide mechanisms may be studied together while recognizing the limitations of translating laboratory findings into human outcomes. This product is intended strictly for in vitro research ONLY. It is NOT approved for human use, clinical application, or human consumption.
Inside the Tesamorelin 10mg + Ipamorelin 3mg Research Formulation
At the chemistry level the vial holds two peptide compounds bound in a fixed 10:3 mass ratio and freeze-dried together. Tesamorelin makes up the larger fraction and ipamorelin the smaller one. Both are supplied dry, and every reconstitution recovers both compounds at their manufactured proportions.
The preparation is not a therapeutic formulation. It carries no approved indication as a paired product, no shared human dosing framework, and no clinical guideline that treats the two peptides together as an intervention. Tesamorelin as an individual compound holds an FDA approval under the trade name Egrifta for a specific human indication.[5] Ipamorelin as an individual compound has been through Phase 2 testing in humans but has no approved therapeutic use of its own.[3] The vial itself sits outside both of those individual product histories and functions as a research reagent.
Formulation Details and Research Specifications
- Blend composition: Tesamorelin 10mg + Ipamorelin 3mg
- Active peptides: Tesamorelin and ipamorelin
- Manufacturer: Novera Compounds
- Brand: Novera
- Country of origin: United States
- Regulatory status: Research peptide, not approved for human use
- Physical form: Lyophilized powder
- Classification: GHRH analog + GH secretagogue blend (GH-axis peptide stack)
- Reconstitution: BAC water or sterile water
- Intended use: In vitro research only
- Package: 1 vial
These characteristics define the formulation supplied for research. They do not create an approved human indication.
Exploring Dual Pathway Activity Within the Growth Hormone Axis
The scientific reason for combining these two peptides comes down to which receptors each one activates. The two entry points to the growth-hormone axis at the pituitary are the GHRH receptor, which tesamorelin binds per its FDA-labeled mechanism[5], and the growth hormone secretagogue receptor GHS-R1a, which ipamorelin binds with a notably clean off-target profile that spared cortisol, prolactin, and the other pituitary hormones tested in its original characterization.[4]
Putting both compounds in one vial lets a laboratory activate the axis through both receptors in a single experimental condition. In preclinical models, GHRH-plus-secretagogue exposure has been studied for how the two inputs combine or interact at the pituitary, and the paired formulation is the material analogue of that experimental design. What the vial does not do is settle whether any interaction observed at the cell or animal level would translate to a clinical outcome. The material lets the question be asked. It does not answer it.
Tesamorelin: The GHRH-Related Component
Inside the paired preparation, tesamorelin acts on the GHRH-receptor side of the axis. Its human profile is the more established of the two compounds. When the FDA approved tesamorelin in November 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy, it did so on the basis of GH-pulsatility restoration and downstream changes in visceral adipose tissue, both of which are outcomes measured in patients rather than in cell culture.[5] That approved use is a piece of context for interpreting research on the compound. It does not, by itself, become an outcome the paired vial produces.
On the metabolic side, a two-week hyperinsulinemic-euglycemic clamp study in healthy men on tesamorelin 2 mg per day reported no meaningful change in insulin-stimulated glucose uptake, even though GH and IGF-1 rose during the dosing period.[1] Any research that lists insulin sensitivity or glucose metabolism among its interests should take this single-agent context into account and should not treat it as a claim about how the blend behaves.
Ipamorelin: The Growth Hormone Secretagogue Component
Ipamorelin’s function inside the vial is to occupy the ghrelin-receptor arm of the axis. Its supporting evidence has a different shape from tesamorelin’s.
Rodent work provides the longest single-agent record. In one twelve-week study in adult female rats, continuous subcutaneous ipamorelin raised bone mineral content and body weight by roughly 6 to 12 per cent.[2] These are preclinical, in vivo findings from a rodent model, and they are the reason “bone and body weight” appears in the ipamorelin literature at all.
Ipamorelin has also been through a randomized, double-blind, placebo-controlled Phase 2 trial in humans, run in postoperative ileus after bowel resection with 117 patients.[3] That trial did not reach its primary endpoint on time to recovery of gastrointestinal function. Ipamorelin therefore has real human safety and pharmacokinetic exposure through the program, but no controlled human efficacy signal on any endpoint and no approved indication of its own. Restatements of the compound as a “recovery and lean mass” agent in humans travel further than the record actually supports.
Research Models and Parameters Associated With the Blend
Reasonable in vitro endpoints for this vial include receptor binding at the GHRH receptor and at GHS-R1a, downstream cAMP or intracellular calcium responses in pituitary-derived cell systems, quantified GH release from cultured pituitary cells or somatotroph-like lines, and selectivity screens against cortisol- or prolactin-associated pathways.
Endpoints commonly attached to the individual peptides in secondary sources, including visceral fat reduction, visceral adipose tissue, lean mass, recovery, exercise adaptation, insulin sensitivity, glucose metabolism, and other metabolic markers, are body-level measurements. They belong to in vivo studies and do not become in vitro endpoints because they appear in a peptide profile. Where they enter this page, they enter as context on the individual compounds’ in vivo literature, cited to the studies that generated them.
A couple of descriptor phrases are worth clarifying. “Advanced body composition stack” describes a research configuration, not an established human outcome. “Growth-hormone axis peptide blend” describes the compound class the vial belongs to, not a therapeutic category. Some laboratories use “tesa ipa blend” as informal shorthand during protocol discussion. Each is fine as descriptive language provided the reader understands it as a category label rather than as evidence.
Research Use Guidelines and Handling Requirements
The preparation stays within qualified research environments. It is not to be injected, ingested, prescribed, self-administered, or otherwise moved into a therapeutic setting under any framing.
Handling should proceed as it would for any research-chemical peptide of this class. That means PPE appropriate to the laboratory setting, controlled storage, refrigeration records on reconstituted material, and disposal of unused material through the institution’s chemical waste channels.
Human safety data for this specific combined vial does not exist as an evidence category. What exists at the human level are two separate single-agent records. Tesamorelin has an FDA-approved label that carries a defined adverse-reaction profile.[5] Ipamorelin has clinical exposure through its Phase 2 postoperative ileus program.[3] These records inform the individual compounds. They do not become a safety dataset for the paired preparation, and the laboratory reading of the blend has to reflect that.
Intended strictly for in vitro research ONLY. NOT for human use, clinical application, or human consumption.
Maintaining Documentation Consistency During Research Use
Reconstitution uses bacteriostatic or sterile water at a volume the laboratory chooses to reach its intended working concentration. There is no single correct volume, since different assays and different cell densities require different concentrations to run properly.
Whatever volume is chosen, the study record should carry the reconstitution medium, the volume, the resulting working concentration, the date and time of preparation, the operator identifier, the storage temperature after reconstitution, and the study or protocol reference. Where tesamorelin ipamorelin blend dosage appears in an experimental note, dosage here means the quantity used in the in vitro protocol, and it has no relationship to a human administration schedule.
For a fixed-ratio blend, batch documentation is more consequential than it is for a single-agent vial. Preparation variability propagates into every experimental condition run against that preparation, and a lot change part way through a study introduces a confound the design is unlikely to have accounted for. The receiving file should include a certificate of analysis on the specific lot, along with a purity and identity record. Sterility testing is not a standard COA element for lyophilized research peptides. It is arranged separately by the laboratory when a particular assay needs it.
Regulatory Classification of the Tesamorelin Ipamorelin Blend
As of September 2026, the paired vial has no therapeutic approval. It is offered under research-use-only terms, and it is not registered as a treatment by the FDA, the EMA, or any other national regulator.
The relevant regulatory context is what exists for the individual compounds rather than for the pair. Tesamorelin holds one specific FDA-approved indication in a defined patient population.[5] Ipamorelin has clinical exposure but no approved indication.[3] The paired preparation does not inherit either individual position and is not, on that basis, a treatment or a prescribable product.
Institutions should verify the local requirements that apply to acquisition, possession, storage, and research use before ordering.
Considerations Before Researchers Buy Tesamorelin 10mg + Ipamorelin 3mg Wholesale
Buying research peptides at institutional scale is a documentation exercise as much as a purchasing one.
Documentation Groups Confirm When They Buy Tesamorelin 10mg + Ipamorelin 3mg at Scale
For laboratories deciding where to buy tesamorelin 10mg + ipamorelin 3mg online for studies that will run for months, the leading concern is usually whether the lot arriving in month six is comparable to the lot arriving in month one. Requesting the certificate of analysis at every receipt and comparing purity and identity across lots is the standard control on that risk. When buying research peptides through institutional channels, that step normally sits with the research office rather than with the individual investigator.
Shipping matters for lyophilized peptide vials because temperature excursions during transit can affect stability, so any receiving procedure should log shipping duration, any temperature indicators used, and how the vial arrived on inspection. Requests to purchase tesamorelin 10mg + ipamorelin 3mg online at institutional volume usually run through the same purchasing pathway the institution uses for other regulated research materials.
Acquisition rules differ by jurisdiction. Institutions that buy tesamorelin 10mg + ipamorelin 3mg wholesale need to confirm the possession, storage, and use frameworks that apply in their location, and groups that buy peptide blend wholesale across parallel studies often want to check for wholesale buying options that preserve batch continuity for the full study window. Programs that buy tesamorelin + ipamorelin blend online generally find that the documentation discipline scales with order size rather than being different at wholesale.
If you want to buy tesamorelin 10mg + ipamorelin 3mg blend for research purposes, customer service representatives at Medical Spa Rx can help. Get in touch today for guidance.
Compliance Notice: The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice. Research-only peptide – intended strictly for in vitro use only.
Citations
[1] Stanley, Takara L et al. “Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.” The Journal of clinical endocrinology and metabolism vol. 96,1 (2011): 150-8. doi:10.1210/jc.2010-1587
[2] Svensson, J et al. “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.” The Journal of endocrinology vol. 165,3 (2000): 569-77. doi:10.1677/joe.0.1650569
[3] Beck, David E et al. “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” International journal of colorectal disease vol. 29,12 (2014): 1527-34. doi:10.1007/s00384-014-2030-8
[4] Raun, K et al. “Ipamorelin, the first selective growth hormone secretagogue.” European journal of endocrinology vol. 139,5 (1998): 552-61. doi:10.1530/eje.0.1390552
[5] U.S. Food and Drug Administration. “EGRIFTA (Tesamorelin for Injection) Prescribing Information.” AccessData, 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
Reviews
There are no reviews yet.